Bausch Health Announces Vyzulta Now Approved in Seven Countries; Expanded Coverage in Canada

Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval in Ukraine, bringing the total number of countries where Vyzulta is approved to market to seven. These countries include Argentina, Canada, Hong Kong, Mexico, Taiwan, Ukraine and the United States.

In Canada, Vyzulta also now has public drug reimbursement in the provinces of Alberta, Saskatchewan, Manitoba, New Brunswick, Newfoundland and Labrador and Nova Scotia, and as part of the federal Non-Insured Health Benefits. These provinces join Ontario, which made Vyzulta available to patients in December 2019.

Additionally, due to a recent formulary change in the United States, Medicare Part D coverage of Vyzulta increased in the United States to approximately 45% up from approximately 30% earlier this year, according to Bausch Health. Vyzulta is indicated in the United States for the reduction of  IOP in patients with open-angle glaucoma or ocular hypertension.

“We are committed to continuing to secure additional regulatory approvals in multiple markets around the world, as well as working to increase access and availability for Vyzulta, because it is an important treatment option for people suffering from glaucoma,” Joseph C. Papa, chairman and CEO, Bausch Health, said in a company news release.